<DOC>
	<DOCNO>NCT02474290</DOCNO>
	<brief_summary>The purpose study evaluate efficacy sorafenib prophylaxis leukemia relapse allogeneic stem cell transplant ( Allo-HSCT ) recipients FLT3-ITD positive acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Sorafenib Prophylaxis Leukemia Relapse Allo-HSCT Recipients With FLT3-ITD Positive AML</brief_title>
	<detailed_description>Internal tandem duplication FMS-like tyrosine kinase 3 ( FLT3-ITD ) mutation report 20 % -30 % patient acute myeloid leukemia ( AML ) . FLT3-ITD-positive AML patient inferior survival , primarily due low complete remission ( CR ) rate high relapse rate . Although allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) improve outcomes FLT3-ITD-positive AML , significant number suffer disease recurrence allo-HSCT . Sorafenib , inhibitor multiple kinase include FLT3 , show promising activity FLT3-ITD-positive AML . Recent study show sorafenib monotherapy combination chemotherapy effective attaining CR , significant improvement relapse . Currently , prophylactic use sorafenib allo-HSCT rarely report , whether improve outcome FLT3-ITD-positive AML remain unclear .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>FLT3ITD Positive AML AlloHSCT Recipients cardiac dysfunction ( particularly congestive heart failure ) hepatic abnormality ( bilirubin â‰¥ 3 mg/dL , aminotransferase &gt; 2 time upper limit normal ) renal dysfunction ( creatinine clearance rate &lt; 30 mL/min ) Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>FLT3-ITD</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>